News for Charles River Laboratories Stock (CRL)

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

PRNewsWire • 02/29/24

Charles River (CRL) Forges Collaboration With Wheeler Bio

Zacks Investment Research • 02/26/24

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

Zacks Investment Research • 02/21/24

Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing

Business Wire • 02/21/24

Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

Business Wire • 02/20/24

The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn't Ignore.

InvestorPlace • 02/15/24

Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript

Seeking Alpha • 02/14/24

Charles River (CRL) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks Investment Research • 02/14/24

Charles River (CRL) Q4 Earnings Surpass, Margins Contract

Zacks Investment Research • 02/14/24

Charles River forecasts strong full-year profit on boost from Noveprim purchase

Reuters • 02/14/24

Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Business Wire • 02/14/24

Unveiling Charles River (CRL) Q4 Outlook: Wall Street Estimates for Key Metrics

Zacks Investment Research • 02/09/24

Charles River (CRL) to Report Q4 Earnings: What's in Store?

Zacks Investment Research • 02/01/24

Charles River (CRL) Launches Animal-Free Endotoxin Test

Zacks Investment Research • 01/30/24

Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test

Business Wire • 01/29/24

Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

Business Wire • 01/24/24

Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call

Business Wire • 01/23/24

Charles River's (CRL) New Launch to Boost Gene Therapy Programs

Zacks Investment Research • 01/18/24

Ten Big Losers To Start The Year. Tesla Isn't The Worst.

Investors Business Daily • 01/16/24

Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing

Business Wire • 01/16/24

The 7 Best Growth Stocks to Buy Now

InvestorPlace • 01/09/24

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Business Wire • 01/08/24

Charles River's (CRL) Memphis Site Achieves Crucial Approval

Zacks Investment Research • 12/19/23

Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration

Business Wire • 12/18/23

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

Zacks Investment Research • 12/13/23